Survey Study for Velaglucerase Alfa (VPRIV) in Japan
About the study
The objective of this post-marketing survey study is to collect data to determine the safety and efficacy of velaglucerase alfa (VPRIV) in participants with Gaucher disease who are new to therapy or have been switched from another therapeutic agent for Gaucher disease.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- Male or female participants with a confirmed diagnosis of Gaucher disease
- Participants who are either naïve to treatment or participants that have been treated with another therapeutic agent for Gaucher disease
- Participants who start VPRIV treatment or transition from VPRIV clinical studies during the enrollment period
EXCLUSION CRITERIA
Exclusion Criteria:
-
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Gaucher Disease
Participants needed
77
Est. Completion Date
Jan 31, 2024
Treatment type
Observational
Sponsor
Takeda
ClinicalTrials.gov identifier
NCT03625882
Study number
SHP-GCB-401
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?